Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coca-Cola

Procter & Gamble

Dividend stocks are particularly attractive when the stock market is down.

Believe It or Not, These Stocks Pay You to Own Them

Bank of Nova Scotia

Dollar General

Realty Income Corp

UnitedHealth Group

Walmart

The amount of years you spend in retirement may vary, yet it's not a bad idea to err on the side of caution. That is, you should build a portfolio that can grow and provide income for 15, 20, perhaps even 30 years.

7 Long-Term Stocks to Buy for a Robust Retirement

Johnson & Johnson has filed a lawsuit against drug distributors and a pharmacy seeking to stop the sale of counterfeit versions of its HIV drugs, months after a similar case brought by Gilead Sciences Inc.

J&J sues to block sales of 'dangerous' counterfeit HIV drugs

Church & Dwight

Host Hotels & Resorts

Sysco

There are stocks that perform well even when there is a large correction. We have identified four stocks with strong momentum justified by technicals and fundamentals.

4 Large Caps At New, All-Time Highs

AbbVie

The list includes high dividend paying stocks that are growing at a steady rate, suitable for income-seeking investors. The post 3 Dividend Stocks for Value Investors Seeking Regular Income appeared first on InvestorPlace.

3 Dividend Stocks for Value Investors Seeking Regular Income

Costco

Kimberly-Clark

Should you consider dividend stocks as market volatility persists?

Best Dividend Stocks To Buy Right Now? 5 For Your Watch List

The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson's longstanding commitment to tackle this challenge The Satellite Center in Cape Town is the second site to open in Johnson & Johnson's network of research collaborations aimed at addressing the world's most pressing health challenges The collaboration between Johnson & Johnson and H3D will help to further expand and strengthen Africa's scientific capacity as a global hub for discovery research CAPE TOWN, South Africa , April 25, 2022 /PRNewswire/ -- Johnson & Johnson (the Company) (NYSE: JNJ) today announced the launch of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. This marks the latest expansion of the J&J Centers for Global Health Discovery (J&J Centers), a global network of research collaborations between the Company and leading research institutions to accelerate translational and discovery research to address some of the world's most pressing global health challenges.

Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)

Schlumberger

Healthcare giant J&J and oilfield-servicing firm Schlumberger were among the larger firms that declared increased dividends last week.

Johnson & Johnson, Schlumberger Boosted Dividends

Caterpillar

Chevron

Deere & Company

Dow Inc

General Electric

Lam Research

Nucor

Raytheon Technologies

Tesla

Exxon Mobil

"The United States has been reclaiming its industrial preeminence in sector after sector after sector," the "Mad Money" host said.

These 12 manufacturers can help investors capitalize on the U.S. 'industrial renaissance,' Cramer says

Deciphera Pharmaceuticals

Eli Lilly

Vertex Pharmaceuticals

Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.

J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy

Disney

Morgan Stanley

"I'm urging you to consider companies that fit the funnel," the "Mad Money" host said Wednesday.

Jim Cramer names 4 stocks that can endure the Fed's 'aggressive tightening cycle'

NEW BRUNSWICK, N.J. , April 20, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the UBS Global Healthcare Conference on Tuesday, May 24 th.

Johnson & Johnson to Participate in the UBS Global Healthcare Conference

Shareholders have larger dividends headed their way.

Why Johnson & Johnson Stock Rose Today

Alabama on Tuesday reached $276 million in settlements with Johnson & Johnson, McKesson Corp and Endo Pharmaceutical, resolving the state's claims that the companies fueled an opioid addiction crisis, the state Attorney General said.

Alabama settles opioid claims against J&J, distributors for $276 million - attorney general

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year.

Johnson & Johnson suspends COVID-19 vaccine sales forecast

Johnson & Johnson on Tuesday said it could no longer provide a forecast for sales of its COVID-19 vaccine, as vaccine hesitancy in low-income countries paired with already low demand in higher-income nations has led to a glut of supply.

J&J suspends sales forecast for COVID vaccine, cuts profit view

Lockheed Martin

Netflix

Market indexes are down to start the day, after rallying to near-flat during Monday's regular session.

Housing Data Up for March; JNJ, LMT Mixed in Q1

Johnson & Johnson (NYSE: JNJ) is, if nothing else, a workhorse among stocks and one any investor could own. The company's business is more than entrenched, it often trades at a discount to the S&P 500, it delivers steady consistent growth, and it pays a nice dividend.

Workhorse Johnson & Johnson Plows New All-Time Highs

At the top of the Dow this morning sits Johnson & Johnson (NYSE:JNJ), last seen up 3.8% at $184.44 and earlier hitting an all-time high of $184.81.

Johnson & Johnson Stock Hits Post-Earnings Record High

J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales.

J&J (JNJ) Beats on Q1 Earnings, Suspends COVID Jab Sales View

Johnson & Johnson (JNJ) stock is on the move Tuesday as investors react to the company's earnings report for the first quarter of 2022. The post Why Is Johnson & Johnson (JNJ) Stock in Focus Today?

Why Is Johnson & Johnson (JNJ) Stock in Focus Today?

Johnson & Johnson (NYSE:JNJ ) Q1 2022 Earnings Conference Call April 19, 2022 8:30 AM ET Company Participants Joe Wolk - Executive Vice President & Chief Financial Officer Jessica Moore - Vice President of Investor Relations Ashley McEvoy - Executive Vice President & Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President & Worldwide Chairman, Pharmaceuticals Thibaut Mongon - Executive Vice President & Worldwide Chairman, Consumer Health Conference Call Participants Larry Biegelsen - Wells Fargo Chris Schott - JPMorgan Joanne Wuensch - Citi Chris Shibutani - Goldman Sachs Louise Chen - Cantor Fitzgerald Josh Jennings - Cowen Terence Flynn - Morgan Stanley Matt Miksic - Credit Suisse Geoff Meacham - Bank of America Danielle Antalffy - SVB Leerink Operator Good morning, and welcome to Johnson & Johnson's First Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference.

Johnson & Johnson (JNJ) Management on Q1 2022 Results - Earnings Call Transcript

Johnson & Johnson (NYSE: JNJ) shares are trading higher Tuesday after the company reported mixed financial results and increased its dividend. Johnson & Johnson said first-quarter revenue grew 5% year-over-year to $23.43 billion, which came in below the $23.67 billion estimate.

News for Johnson & Johnson Stock (JNJ)